	US 11,987,639 B2
	Trophoblast glycoprotein (5T4, TPBG) specific chimeric antigen receptors for cancer immunotherapy
Cecile Schiffer-Mannioui, Villiers-sur-Marne (FR)
Assigned to CELLECTIS
Filed by CELLECTIS, Paris (FR)
Filed on Jul. 24, 2020, as Appl. No. 16/938,576.
Application 16/938,576 is a division of application No. 15/506,643, granted, now 10,759,868, previously published as PCT/EP2015/070128, filed on Sep. 3, 2015.
Claims priority of application No. PA201470543 (DK), filed on Sep. 4, 2014.
Prior Publication US 2020/0407461 A1, Dec. 31, 2020
Int. Cl. C07K 16/30 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 14/735 (2006.01); C07K 19/00 (2006.01); C12N 5/078 (2010.01); C12N 5/0783 (2010.01)

CPC C07K 16/30 (2013.01) [C07K 14/705 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70535 (2013.01); C07K 14/70578 (2013.01); C07K 19/00 (2013.01); C12N 5/0634 (2013.01); C12N 5/0636 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C07K 2319/70 (2013.01); C07K 2319/74 (2013.01); C12N 2510/00 (2013.01)]

16 Claims

1. A polynucleotide encoding a 5T4 (NTRKR1) specific chimeric antigen receptor (CAR) comprising (i) an extracellular ligand binding-domain comprising a variable heavy chain, a variable light chain, a CD8α hinge, and a CD8α transmembrane domain and (ii) a cytoplasmic domain comprising a CD3 zeta signaling domain and a co-stimulatory domain from 4-1 BB, wherein said variable heavy chain comprises CDR regions as set forth in SEQ ID NO:48, SEQ ID NO:49, and SEQ ID NO:50, and wherein said variable light chain comprises CDR regions as set forth in SEQ ID NO:51, SEQ ID NO:52, and SEQ ID NO:53.